Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).

Details

Language :

English

ISSN :

0732183X

Volume :

42

Issue :

2

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

174637352

Full Text :

https://doi.org/10.1200/JCO.22.02915